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Abstract: The purpose of this study was to evaluate the level of mitotic cyclin B1 in the context of senescence
and cell death in A549 non-small cell lung carcinoma cells. This was performed through analysis of the cell
cycle, the percentage of SA-b-galactosidase-positive, as well as TUNEL-positive cells. Morphological alter-
ations were studied using a transmission electron microscope. Changes in the intracellular level and the pres-
ence of cyclin B1 in the nucleus and cytoplasm areas were detected by flow cytometry and confocal fluores-
cence microscopy, respectively. In the cells exposed to various concentrations of doxorubicin, different kinds
of cell death and senescent phenotype were observed. Alterations in the cell cycle and increased polyploidy
may be indicative of mitotic catastrophe execution. Changes in cyclin B1 may also be strictly related to its
different regulation at mitotic catastrophe and senescence programs. (Folia Histochemica et Cytobiologica
2012, Vol. 50, No. 1, 58–67)
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Introduction
Cyclin-dependent kinases (CDKs) mediate cell cycle
progression by phosphorylating different substrates
at specific cell cycle phases. Through proper synthe-
sis and regulation of cyclins, CDKs are activated in
a controlled manner.
Cyclin B1 forms with cdc2 (Cdk1) a complex called
‘mitotic promoting factor’ (MPF) that is crucial for
G2/M transition [1]. Thus, insufficient levels of cyclin
B-Cdk1 complexes, e.g. as a result of attenuation of cy-
clin B1 promoter by p53, are related to cell cycle arrest
at G2 [2]. Production of cyclin B1 in the cytoplasm dur-
ing S-phase is followed by its transport to the nucleus at
late G2 phase and, finally, its subsequent removal dur-
ing anaphase via an ubiquitin-related pathway [3].
There are reports suggesting that changes in the reg-
ulation of cyclin expression may be involved not only in
unrestrained cell growth and malignant transformation,
but also in tumor suppressor mechanisms [4]. Exposure
to anti-cancer drugs can cause not only apoptosis but
also non-apoptotic mechanisms inducing cell death such
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as senescence and mitotic catastrophe. A hypermitoge-
nic cell cycle arrest in G1 or G2 may be observed after
induction of senescence in cancer cells [5]. Stress-in-
duced premature senescence is independent of telom-
ere length and could result from the action of antican-
cer drugs. There are several symptoms of senescence
on the cellular level, including flattened and enlarged
cell shape, increased cytoplasmic granularity, lipofuscin
accumulation, enhanced senescence-associated b-galac-
tosidase activity, as well as changes in expression of the
critical cell cycle regulatory tumor suppressor genes [6–
10]. From these genes, p53 and p16 are the most com-
monly mutated in different types of cancer and they are
implicated in the execution of senescence program via
different transduction pathway.
Another common tumor suppressor mechanism
activated by anticancer drugs is apoptotic cell death. It
consists of biochemical and morphological alterations
leading to removal of cells without induction of inflam-
mation. Mitotic catastrophe is generally considered to
be a kind of cell death resulting from mitotic failure
that can be accompanied by micronucleation and multi-
nucleation; but on the other hand, some polyploid cells
may survive and undergo depolyploidization. Cell death
as a result of abnormal mitosis may be related to pre-
mature activity of cyclin B1/Cdk1 in the nucleus area
and chromatin condensation. Moreover, there are
some suggestions that cyclin B1 is crucial for the exe-
cution of mitotic catastrophe [11]. However, little is
yet known about changes in the expression of cyclin
B1 in the process of senescence.
In this work, we would like to verify if changes in
cyclin B1 level might be related to the regulation of
senescence and/or cell death programs induced by
doxorubicin in A549 cells.
Material and methods
Cell culture and treatment. The human non-small cell lung
carcinoma cell line A549 was kindly provided by P. Kopiń-
ski, Ph.D. (Department of Gene Therapy, Ludwik Rydy-
gier Collegium Medicum in Bydgoszcz, Nicolaus Coperni-
cus University in Torun, Poland). The cells were cultured
in monolayers at 37°C in a humidified CO2 incubator (5%
CO2) in DMEM (Gibco) with the addition of 10% fetal
bovine serum (FBS; Gibco) and 50 μg/ml of gentamycin
(Sigma-Aldrich). Doxorubicin (Adriblastin PFS; Pharma-
cia Italia S.p.A., Pfizer Group) was diluted in sterile water
and was added to the cell culture in appropriate doses.
Twenty-four hours after seeding, the cells were exposed to
doxorubicin (50, 100, 200 nM) for 72 h. Thereafter, the
cells were incubated in a drug-free medium for a further
72 h, and the subsequent experimental procedures were
performed.
Cell cycle analysis. The cell pellet obtained after trypsiniza-
tion and washing with PBS was suspended in 1 ml of NSS solu-
tion (50 μg/ml PI, 0.0112% (w/v) sodium citrate (Sigma-Ald-
rich); 0.03% (v/v) nonylphenylpolyethylene glycol (Nonidet P40
Substitute; Fluka). The cells were centrifuged (5 min at 300 × g)
and resuspended in 250 μl of NSS. After incubation in the dark,
(15 min, RT), the cells were incubated in the same conditions
in the presence of RNase A solution (250 μl; 10 μg/ml RNase
A in PBS) (Sigma-Aldrich). Thereafter, 0.5 ml PBS was added
and the cells were analyzed using a flow cytometer (FACScan;
Becton–Dickinson). Cell cycle distribution was estimated us-
ing CellQuest software (Becton–Dickinson). For each sam-
ple, 20,000 events were acquired and the nonclumped cells
were gated for further measurements.
TUNEL assay. DNA fragmentation was measured by the
terminal deoxynucleotidyl transferase-mediated dUTP nick-
end labeling (TUNEL) method using a commercially avail-
able kit (APO-DIRECT, BD Biosciences Pharmingen), ac-
cording to the manufacturer’s instructions as described by
Litwiniec [6].
Senescence-associated b-galactosidase assay. Senescence-
-associated b-galactosidase activity was determined using the
Senescent Cells Staining Kit (Sigma-Aldrich), according to
the manufacturer’s protocols. Briefly, after fixation proce-
dure, the cells were incubated overnight in the presence of
a staining solution containing X-gal (5-bromo-4-chloro-3-in-
dolyl-b-galactopyranoside) in the dark (37°C). The percent-
age of blue-stained cells was determined by light microscopy
(Eclipse E800, Nikon). Results were presented as the mean
number of SA-b-galactosidase positive cells per 100 cells.
Transmission Electron Microscopy (TEM). Conventional elec-
tron microscopy was used to visualize A549 morphology at the
ultrastructural level. The control and treated cells (day 3) were
harvested by trypsinization, washed with PBS and fixed in 3.6%
glutaraldehyde (pH 7.2, Merck) (30 min, RT). After washing
in 0.1 M sodium cacodylate buffer (pH 7.2, Sigma-Aldrich),
the cells were postfixed in 2% buffered OsO4 for 2 h, dehy-
drated in ethanol (40–100%), and embedded in Epon E812.
Semithin sections were stained with 1% toluidine blue and used
for targeting the cells. Ultrathin sections (40 nm thick) were
double-stained with uranyl acetate (Chemapol, Prague, Czech
Republic) and lead citrate (BDH, Poole, UK). The material
was examined using a transmission electron microscope JEM
100 CX (JEOL, Tokyo, Japan).
Flow cytometric analysis of cyclin B1 expression. Cells
grown on six-well plates were trypsinized, washed with PBS,
centrifuged (5 min, 300 × g) and resuspended at a final
concentration of 1–2 × 106cells/ml in 1 ml PBS with the
addition of 100 μl of formaldehyde (Polysciences, Inc). Af-
ter incubation on ice (15 min in the dark) and subsequent
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centrifugation (5 min, 300 × g), the cell pellet was perme-
abilized by the addition of 2 ml of ice-cold 50% (v/v) meth-
anol (JT Baker). Then cells were incubated for 15 min on
ice, washed twice with cold PBS, and resuspended in 100 μl
of PBS. For intracellular staining, the cell suspensions were
transferred into flow cytometric tubes containing 20 μl of
mouse monoclonal cyclin B1 antibody: sc-7393 (Santa Cruz
Biotechnology, Inc) and 20 μl of normal mouse IgG1 Alexa
Fluor 488: sc-3890 (Santa Cruz Biotechnology, Inc). Fol-
lowing a 30-min incubation on ice and washing with PBS,
the cells were centrifuged (5 min, 500 × g) to wash off ex-
cess antibody, and were resuspended in 200 μl of PBS for
flow cytometric analysis on FACScan (Becton–Dickinson),
according to the manufacturer’s instructions, with some
modifications as described by Litwiniec [6].
CellQuest software (Becton–Dickinson) was used to cal-
culate the percentage of cyclin B1-positive cells and the mean
fluorescence intensity of these cells for each experimental case.
Immunofluorescence assay. Cells on coverslips were briefly
washed with PBS, fixed in 4% paraformaldehyde (15 min, RT)
and then washed with PBS (3 × 5 min). After that, the cells
were incubated in permeabilization solution (0,1 % Triton
X-100 in PBS) and blocked with 1% BSA. After permeabiliza-
tion, the cells were incubated with mouse monoclonal cyclin
B1 antibody: sc-245 (Santa Cruz Biotechnology, Inc) (45 min,
RT), washed three times with PBS and incubated with anti-
mouse IgG TRITC conjugated antibody (Sigma-Aldrich)
(45 min, RT, in the dark). Nuclear staining was performed
with DAPI (Sigma-Aldrich). After incubation, the cells were
washed with PBS and then mounted on slides in Aqua Poly/
/Mount (Polysciences, Inc). Both cyclin B1 and DAPI stain-
ing were examined using confocal microscopy (C1, Nikon).
Statistical analysis. The analysis was performed using sta-
tistical software (GraphPad Prism, San Diego, CA, USA).
The data was compared by the nonparametric Mann–Whit-
ney U test, and the changes were considered statistically
significant at the level of p < 0.05.
Results
Cell cycle
As cell cycle distribution may reflect cellular response
to drug treatment, we determined the percentage of
cells in each phase of the cycle. The percentage of
cells in the G0/G1 phases decreased in comparison
with the control cells, although the tendency of the
percentage seemed to increase dose-dependently
(Figures 1A, 2). On the other hand, the fraction of
cells with DNA content typical of S phase of the cell
cycle did not change statistically after treatment, apart
from the highest concentration of the doxorubicin
Figure 1. Flow cytometry analysis of the cell cycle distribution of A549 cells stained with RNase/PI. A diagram for each of
the groups defined according to DNA content is shown. A: Cells with DNA content corresponding to G0/G1 phases.
B: Cells with DNA content corresponding to S phase. C: Cells with DNA content corresponding to G2/M phases.
D: Cells with DNA content corresponding to subG1 fraction. E: Cells with DNA content corresponding to polyploidy.
Columns — median percentage of cells; bars — interquartile range. Asterisks denote statistical significance compared to
control cells (p < 0.05). Results are representative of five independent experiments
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(200 nM), at which the percentage increased (Fig-
ures 1B, 2) (Mann–Whitney U, p < 0.05).
As regards G2/M phases, we observed an in-
crease in the percentage of cells with DNA con-
tent typical of these phases; this increase was most
visible at the highest dose of doxorubicin (Figures
1C, 2). The subG1 fraction, which represents events
indicative of DNA fragmentation, seemed to in-
crease as compared with the population of control
cells, but the difference was statistically significant
only at 100 nM concentration of doxorubicin (Fig-
ures 1D, 2). Similarly, the percentage of polyploidy
was visibly higher after drug treatment; however,
the tendency decreased at the highest concentra-
tion of doxorubicin in comparison with lower con-
centrations of doxorubicin used in the study (Fig-
ures 1E, 2).
Senescence and cell death
In order to study the effect of doxorubicin on the A549
cells, we analyzed cell survival using the trypan blue ex-
clusion dye method, the activity of SA-b-galactosidase,
DNA fragmentation and cell ultrastructure in TEM.
Figure 2. Flow cytometry analysis of the cell cycle distribution of A549 cells stained with RNase/PI. Representative
histograms are shown: upper left — control; upper right — 50 nM of doxorubicin; lower left — 100 nM of doxorubicin;
and lower right — 200 nM of doxorubicin. According to DNA content, five categories of cells were distinguished: 1) cells
with DNA content corresponding to G0/G1 phase; 2) cells with DNA content corresponding to S phase; 3) cells with DNA
content corresponding to G2/M phase; 4) cells with fractional subG1 phase; and 5) cells with polyploid DNA content
Figure 3. Flow cytometry analysis of DNA fragmentation
using the TUNEL method. Columns — median percentage
of TUNEL-positive cells; bars — interquartile range.
Asterisks denote statistical significance compared to
control cells (p < 0.05). Results are representative of five
independent experiments
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The analysis of DNA fragmentation by TUNEL
method revealed that the fraction of cells with DNA
single or double strand breaks was significantly
higher after the treatment compared to the con-
trol cells (Figure 3), although a tendency of this
increase was not dose-dependently elevated. The
highest fraction of TUNEL-positive cells was ob-
tained for 200 nM doxorubicin (Figure 4). On the
other hand, results of the trypan blue exclusion dye
method showed that the viability of the cells de-
creased gradually (dose-dependently) after doxoru-
bicin treatment compared to the control cells (Fig-
ure 5). Similarly, we observed enhanced SA-b-galac-
tosidase activity reflected by the increased percent-
age of SA-b-galactosidase-positive cells at 50, 100 and
200 nM doxorubicin (Figure 6).
There were also observed changes in morphology
of the cell revealed at the ultrastructural level. These
changes were related to alterations in nuclear and cy-
toplasmic compartments, such as: increased volume of
the cell, large amount of electron-dense and electron-
transparent structures including lamellar bodies, lipo-
fuscin-like and vacuole-like vesicles as well as disorga-
nization of some cellular membrane systems (ER, AG)
Figure 4. Flow cytometry analysis of DNA fragmentation using the TUNEL method. Representative histograms are
shown: upper left — control; upper right — 50 nM of doxorubicin; lower left — 100 nM of doxorubicin; and lower right
— 200 nM of doxorubicin. The percentage of TUNEL-positive cells is shown on horizontal lengths
Figure 5. The effects of doxorubicin doses on cell viability.
Columns — median percentage of survival cells;
bars — interquartile range. Asterisks denote statistical
significance compared to control cells (p < 0.05). Results
are representative of ten independent experiments
and appearance of abnormally-shaped nuclei which
may be indicative of mitotic catastrophe (Figure 7).
Apart from that, we observed few intranuclear inclu-
sions. However, typical senescence-associated hetero-
chromatin foci were not visible in our experiment.
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Figure 6. Activity of SA-b-galactosidase in A549 cells treated with doxorubicin. A: Control cells. B: Cells treated with
50 nM doxorubicin. C: Cells treated with 100 nM doxorubicin. D: Cells treated with 200 nM doxorubicin. Changes in
morphology are shown. Visible increase in volume of the cells (C, D) in comparison with the control cells (A).
An enhanced activity of SA-b-galactosidase in the cells exposed to doxorubicin (B, C, D) in comparison with the control
cells (A). Results are representative of ten independent experiments
Figure 7. The ultrastructure of A549 cells treated with doxorubicin. A: Control cells. B: Cells treated with 50 nM doxoru-
bicin. C, D: Cells treated with 100 nM doxorubicin. E, F: Cells treated with 200 nM doxorubicin. Alterations of the
cytoplasm and cell nucleus are shown: large amount of electron-dense (B, D, F) and electron-transparent (D) structures
including lamellar bodies (C), lipofuscin-like and vacuole-like vesicles (D) as well as disorganization of some cellular
membrane systems (ER, AG) (C) and appearance of abnormally-shaped nuclei (C, E). Results are representative of five
independent experiments. Bar = 1 μm
A B
C D
A C
B D
E
F
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Cyclin B1
Cytometric analysis of cyclin B1 showed that the percent-
age of cyclin B1-positive cells decreased gradually after
treatment with increasing concentrations of doxorubicin,
which is consistent with the results of cell viability ob-
tained in our conditions. As regards a level of cyclin B1 in
the cyclin-positive cells, we observed an increase in the
mean fluorescence intensity of this protein (Figure 8).
Additionally, confocal microscopic examination showed
cytoplasmic and nuclear localization of cyclin B1. In con-
trol cells, cytoplasmic localization was more prominent,
whereas in the cells exposed to doxorubicin, cyclin B1
was more abundant in the nucleus area (Figure 9).
Discussion
The aim of this work was to evaluate the level of mi-
totic cyclin B1 in the context of senescence and cell
death. A previous study was performed in which an
unstable senescence-like program was shown to be
induced in A549 cells after treatment with similar
concentrations of doxorubicin [6].
Figure 8. Flow cytometry analysis of cyclin B1 content in A549 treated with doxorubicin. Representative histograms of five
independent experiments are shown: upper left — control; upper right — 50 nM of doxorubicin; lower left — 100 nM of
doxorubicin; and lower right — 200 nM of doxorubicin. The percentage of cells with cyclin B1 expression is shown on
horizontal lengths; MFI — mean fluorescence intensity
On the other hand, in the present research, we
wanted to verify if a longer recovery time could result
in a more stable and effective senescence process. As
in the previous studies, we observed an induction of
different kinds of death and senescence features in
the population of cells exposed to doxorubicin. After
the doxorubicin treatment, there was a visible increase
in the percentage of cells typical of G2/M phases of
the cell cycle, but also an increased polyploidy, which
may be indicative of mitotic catastrophe execution.
At the highest dose of the drug, the number of
endocycling cells decreased, which may reflect either
a more effective G2/M arrest or an increased percent-
age of cells dying due to mitotic catastrophe. Previ-
ously, an increase in the percentage of cells in the
G2/M phase of the cell cycle, as well as an increase in
the number of cells with more G2/M content, was
observed (50 and 100 nM of doxorubicin); however,
at 200 nM of doxorubicin, there occurred a visible
decrease in the number of cells with more G2/M DNA
content in comparison with 50 and 100 nM of dox
(which was confirmed statistically by Tuckey’s multi-
ple comparison test, p < 0.001).
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Figure 9. Confocal microscopic examination of cytoplasmic and nuclear localization of cyclin B1 in A549 cells treated with
doxorubicin. Cells were treated with 50, 100, and 200 nM doxorubicin and immunolabeled for the presence of cyclin B1.
Cell nuclei were labeled with DAPI
Nevertheless, as regards a stable cell cycle arrest, it
seems that senescence associated heterochromatin foci,
which would be related to a permanent senescence
program, did not appear. Instead, at the highest dose
of doxorubicin, there was also the highest percentage
of TUNEL-positive cells. An increased fraction of
TUNEL-positive cells at the lowest drug concentra-
tion (50 nM) may reflect the presence of DNA strand
breaks that are non-lethal and, as a result, some of these
cells may recover. This assumption was further con-
firmed by the evaluation of viability, which revealed
a dose-dependent decrease in living cells fraction.
Therefore it seems that the highest percentage of cells
undergoing repair was observed at a 50 nM concentra-
tion of doxorubicin, whereas the highest concentration
resulted in the induction of mitotic catastrophe.
In the present study, we observed an increase in
the fluorescence intensity of cyclin B1. Perhaps this
was related to a transiently elevated level of this pro-
tein as a consequence of mitotic catastrophe execu-
tion after a low-dose doxorubicin treatment. It was
previously revealed that treatment with different con-
centrations of doxorubicin may have various effects
on cancer Huh-7 cells as regards a cell death mode as
well as levels of cyclin A and cyclin B [12]. Moreover,
this study showed that the decision concerning cell
death modality is strictly correlated with Cdk1 and
Cdk2 activities. These seemed to be crucial for the
execution of mitotic catastrophe [12]. It has been sug-
gested that polyploidization associated with the se-
nescent cell morphology appearing after DNA dam-
age may result from degradation of cyclin B1 [13].
Cell cycle arrest may also be accompanied by alter-
ations in cyclin B1 level. For example, a decrease in
cyclin B1 levels was observed during hyperoxic stress
in A549 cells, which resulted in growth inhibition. This
effect was explained by increased proteolysis of cy-
clin B1 or, alternatively, by the action of inhibitory
proteins, like p21 or 14-3-3d, which may act directly
on the Cdk1-cyclin B1 complex [14].
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On the other hand, Dan and Yamori [15] suggest-
ed that changes in the level of cyclin B1 and G2/M
arrest in A549 cells exposed to doxorubicin are regu-
lated in the manner independent of p53, because sim-
ilar changes were not induced by cisplatin, a well-known
p53 activator [15]. In agreement with that, it was shown
that an increased level of cyclin B1 may appear in some
G2/M-arrested cancer cells with defects in p53 [16].
However, we could not exclude that the increase in
the cyclin level observed by us may be strictly correlat-
ed with morphological changes appearing in this pop-
ulation of cells after treatment with doxorubicin.
Cyclin B1, apart from other cyclins, is often con-
sidered as a potential prognostic marker in different
diseases, particularly in cancer [17–21]. For example,
it has been shown that cyclin B1 increases during mi-
totic catastrophe execution induced by different phar-
macological or genetic factors. This has been de-
scribed, for example, in colon cancer cells exposed to
doxorubicin [22].
One of the causes of mitotic catastrophe execu-
tion may be premature entry into mitosis before the
completion of DNA replication, which results in ab-
normal organization of chromosomes in the pres-
ence of the high activity of cyclin B1/Cdk1 complex
in the nucleus area [11, 23]. There are suggestions
that such an aberrant mitosis is mediated by Notch
inhibition followed by NF-kB activity, which in turn
induces high levels of cyclin B1 [24]. Increased Cdk1/
/cyclin B1 activity seems also to be crucial for effi-
cient cell killing in cases of apoptosis [25, 26]. In
accord with that, it has been shown that nuclear ac-
cumulation of cyclin B1 is one of the factors involved
in triggering this kind of cell death, as it was found
mainly in the cytoplasm of the cells that were apop-
totic-resistant and accumulated in the nucleus of the
apoptotic-prone ones [27]. Moreover, it has been
proven that targeting cyclin B1 protein by RNAi or
chemical inhibitors leads to decreased number of
apoptotic HT29 cells after treatment with camptoth-
ecin [23]. On the other hand, reduction of cyclin B1
level may also induce cell cycle arrest and apoptosis
in some cancer cells [28].
In our study, we observed that a longer recovery
time was related to an increased number of G2/M
arrested cells. However, apart from these cells, the
fraction of polyploid cells was still quite high. Only at
the highest dose of the drug might a cell cycle arrest
be more efficient, as indicated by increased G2/M
content in comparison with poliploidy.
It is tempting to hypothesize that this could re-
flect a more stable senescence program. Concomi-
tantly, at 200 nM doxorubicin, the level of cyclin B1
seemed to decrease compared to 100 nM. These
changes in cyclin B1 levels may suggest that this pro-
tein is differently regulated at mitotic catastrophe to
senescence transition.
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